Member Info for volcano

bunny you are on the wrong wagon get off

will go down to cash value of 7.1p i think

funding it is the problem here if they do not get it tomorrow this will go down

DINDI are you buying then

so you looking for 20% rise to break even i hope you get it mate

how much you have payed

Cancer drug setback hits Antisoma By John O’Doherty Published: March 29 2010 16:15 | Last updated: March 29 2010 16:15 Shares in Antisoma fell almost 71 per cent on Monday – wiping more than £130m off the drugmaker’s market capitalisation – following news that one of its key cancer drugs did not prolong life in humans. “We are mortified about this result both for patients and our shareholders,” said Glyn Edwards, chief executive. EDITOR’S CHOICE Europe halts sale of Indian-sourced drug - Mar-27.EU steps up drug groups’ probe - Jan-12.AstraZeneca ties up with Indian drugmaker - Mar-11.White House tilts at barrier to cheap drugs - Feb-22..“This drug has shown very strong activity pre-clinically in animals, and very strong activity in Phase I and Phase II, and that’s why this result was so unexpected and surprising. “But it [drug development] is a risky business, and that’s why we try as best we can to build a portfolio of opportunities. While we will be a smaller company going forward, there is still value in our other programmes.” The lung cancer drug was undergoing Phase III trials, the final stage in clinical testing before a drug can be marketed. However, it was decided to halt the trial because further testing would be “futile” given the fact that there was “little or no prospect of demonstrating a survival benefit”. Antisoma had in-licensed the drug, ASA404, from the development arm of the charity now known as Cancer Research UK and had in turn out-licensed the drug to Novartis to conduct the study. The study comprised 1,200 cancer patients who had on average been taking the drug for six months. ASA404 was administered every three weeks for six treatments as an intravenous drip immediately after chemotherapy. Mr Edwards said that in spite of the failure of ASA404, the company had still made about $100m (£67m) in one-offs and milestone payments from Novartis who licensed the drug towards the end of Phase II. “Lung cancer drugs often fail,” said Paul Cuddon, an analyst at KBC Peel Hunt, who believes the earlier Phase II trial may not have recruited a sufficient number of patients. “There’s probably been eight Phase II or Phase III failures for lung cancer drugs over the past 12 months, so Antisoma and Novartis are not alone here.” Although ASA404 was the company’s lead product, Antisoma now has two other drugs in clinical trials. Both are targeted at treating leukaemia, with one in Phase III and the other in Phase II. The group has a further drug in development to treat auto-immune disease that has not yet entered clinical trials. Antisoma now has £45m in cash left, which the group said was enough to fund it through to the end of 2011, by which time it will have results from both of the clinical trials for the leukaemia portfolio. Antisoma

LONDON (ShareCast) - Shares in cancer drug developer Antisoma (LSE: ASM.L - news) have fallen by more than two-thirds following news that Novartis (Virt-X: NOVN.VX - news) has halted a Phase III trial for lung cancer treatment ASA404. There is concern about the continued support of Novartis. An initial assessment of the data showed that there was not going to be a positive result to the trial. The Phase II trial had shown very positive results so this is a shock. A second trial will continue to the interim stage in late 2010 but is there are no positive expectations for this trial either. There is £45.1m in the bank which should last until late 2011. Secondary acute myeloid leukaemia treatment AS1413 is the main hope for Antisoma. Results from a Phase III trial are due later this year. Antisoma is looking for a major partner for this drug. KBC Peel Hunt believes the company is a potential bid target.

Antisoma shares plunged to a new low today after the drug developer's potential treatment for lung cancer failed a clinical test. The shares fell by as much as 72 per cent to just 9p after the biotechnology company, which specialises in trying to develop cancer drugs, halted its trial of ASA404 in the late stages because it found little or no prospect of demonstrating a survival benefit to patients. The treatment, which Antisoma had been developing with the Swiss drug giant Novartis, had been seen as the British company's best hope of bringing a drug to market. Novartis had been looking to file ASA404 for approval next year. Glyn Edwards, the chief executive of Antisoma, said that ASA404 is unlikely to generate any cash in the future and he will need to cut costs, which may include job cuts. Related Links Reed hopes it’s third time lucky in challenging outlook Tempus: Helphire can hammer out a few dents Trouble Brewin over policies Samir Devani at Nomura Code, the broker, told clients they should no longer buy Antisoma shares. Mr Devani reckoned the lung cancer drug had accounted for about 80 per cent of the value he had placed on the company. He now values the shares at 12p. Piper Jaffray, another broker, described the failure as "unexpected and extremely disappointing news", particularly after such encouraging results in earlier trials. Analysts there slashed the target price for the shares from 69p to 15p. Mr Edwards said that his company has enough cash to last through this year, and he will look to find partners for the company's other drug to raise funds. ASA404 was one of two drugs from Antisoma in the final stage of trials. The other is a treatment for leukaemia, AS1413.

anyone buying at 9p ,could bounce back tomorrow to 12p

wait

BL i would sell some now they had good run for wail

LONDON, March 22 (Reuters) - European shares pared losses on Monday afternoon, with gains in food producers and tobacco stocks offsetting falls in banks and oil majors as investors reassess worries over debt problems in Greece. By 1521 GMT, pan-European FTSEurofirst 300 index shed 0.1 percent at 1,064.02 points, well off its session low of 1,052.04 points. Banks pared some earlier losses, with traders attributing the move to an easing in concerns over Greece's debt situation. Barclays, HSBC, BNP Paribas and Deutsche Bank lost 0.5 to 1.1 percent. 'Since the U.S. markets have opened, the euro has bounced somewhat and the dollar has given back some of its early gains and they're saying ... Greece is too small to worry about,' a trader said. On the upside, defensive food producers were higher, with Associated British Foods, Lindt & Spruengli and Nestle up 0.3 to 1.3 percent. U.S stocks rose, led by the healthcare sector, after the House of Representatives passed a healthcare reform bill, providing clarity following months of uncertainty. In Europe, pharmaceutical stocks regained some earlier losses, with GlaxoSmithKline, AstraZeneca, Merck and Shire up 0.8 to 1.2 percent. (Reporting by Harpreet Bhal) Keywords: MARKETS EUROPE STOCKS/GAINS (harpreet.bhal@thomsonreuters.com; +44 207 542 4533; Reuters Messaging: harpreet.bhal.thomsonreuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Next Article: UPDATE 1-BA strike extends into third day, union wants talks Back to Finance News Home | Share Prices | Share Chat | Finance Tools | Finance News | Contact | About Us | Sitemap | Web Design by Revive Digital Media | Terms & Conditions

another good day now we want RGD to be mention in one of weekend papers .nice weekend all .volcano

HI everybody we had a fantastic day today and i hope more to come ,i have spoken to RGD today and the results will be announced in end of march not in the mid march as they stated in there trading update ,i have been told everything it is OK and company making very good progress . NOW where is that cup of tea with two Sugars , all helps .volcano

yes i have to admit i have been rampin RGD everywhere .volcano

this is what we are looking forward to; As a result of this strong progress at all its business units, the Group expects to report profits before taxation and exceptional items for the year ended 31 December 2009, which are around 25% above current market expectations. Real Good Food expects to announce its preliminary results in mid-March.

more workers in the USA and maybe more set top boxes why not .volcano LONDON, March 4 (Reuters) - European shares extended gains on Thursday after data showed the number of U.S. workers filing new applications for unemployment insurance fell last week, while those continuing to receive benefits dropped to the lowest level in over a year. By 1350 GMT, the pan-European FTSEurofirst 300 index of top shares was up 0.3 percent at 1,038.19 points after being as low as 1,028.77. The market also got some support after European Central Bank President Jean-Claude Trichet said inflation expectations remain firmly anchored and the economic recovery in the euro area is on track. Banks added the most points to the index. Banco Santander , UBS, BBVA and Barclays were up 1.4 to 2.3 percent. (Reporting by Joanne Frearson) Keywords: MARKETS EUROPE STOCKS/GAINS (joanne.frearson@thomsonreuters.com; +44 207 542 2773, Reuters Messaging:joanne.frearson.thomsonreuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.

hi all, this is in the IC coming out tomorrow should help a little .volcano Pre-tax profits for 2009 at set-top-box maker Pace surged to £69.9m from £13.8m a year ago on the back of a 52 per cent rise in revenues. But, with the upcoming football World Cup driving demand for more basic units, average selling prices over 2010 are expected to be lower than last year's £66 and so management expects that percentage sales growth will only be in mid single-digits this year. Advertising Pace shipped 17.2m set top boxes in 2009, 31 per cent more than in 2008, making it the number two provider to the PayTV industry. Separately, Pace announced the acquisition of French IP and cable gateway company Bewan Systems, which will be integrated into Pace France. The group still has a strong balance sheet with net cash of £76.5m. What we said: Buy When: 27/04/09 Price: 164p -------------------------------------------------------------------------------- SHARE TIP UPDATE: BuyGrowth may slow this year but, globally, high-definition TV has a penetration rate of just 4 per cent, which leaves big potential for set-top box providers. Pace's share price has advanced 15 per cent since we recommended buying the shares, but the longer-term growth story remains. At 189p, still a buy. -------------------------------------------------------------------------------- Order reprintsShareBack to top Recommend -------------------------------------------------------------------------------- Comments in chronological order Report item as: (required) X Obscenity/vulgarity Hate speech Personal attack Advertising/Spam Copyright/Plagiarism Other Comment: (optional) Share Tips BuysSellsRecommendation changesTip performanceTrading Companies Markets and Sectors Columnists Stock Screens Funds Data Research Tools Investment guides Events Q and A requires IC Advantage -------------------------------------------------------------------------------- Subscribe today Celebrate our 150th anniversary with fantastic savings on a joint magazine and IC Advantage subscription. Subscribe today and save £150

Hi GEML i hope you have not invested all your profits from AEX in to here <ouch > good luck mate you would need it here .volcano